Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Arch Gynecol Obstet. 2011 Jan;283(1):133-4. doi: 10.1007/s00404-010-1501-6. Epub 2010 May 15.
Dasatinib is a highly potent Bcr-Abl inhibitor that is approved for the treatment of imatinib-resistant or -intolerant chronic myeloid leukemia (CML). The potential effects of dasatinib on sperm counts, sperm function, and fertility have not been studied yet. There is only one report in the medical literature of successful pregnancies while patients were taking dasatinib, thus making our case the second report. Here, we present the case of a 38-year-old man who conceived a healthy baby while on dasatinib therapy.
达沙替尼是一种高效的 Bcr-Abl 抑制剂,已被批准用于治疗伊马替尼耐药或不耐受的慢性髓性白血病 (CML)。达沙替尼对精子数量、精子功能和生育能力的潜在影响尚未得到研究。在医学文献中只有一份报告显示患者在服用达沙替尼时成功怀孕,因此我们的病例是第二份报告。在这里,我们报告了一例 38 岁男性在接受达沙替尼治疗期间成功孕育健康婴儿的病例。